Abstract
Materials and methods Autologous CD4 T lymphocytes from HIV-infected subjects were genetically modified ex vivo with the vector, expanded, and 10-80 billion vector-modified cells were reinfused into patients. Longitudinal effects of the therapy on HIV-1 env evolution were analyzed in 17 subjects sampled both pre-infusion and monthly postinfusion for 6 to 12 months. Plasma-derived viral RNA from 144 samples was amplified, cloned, and the fulllength gp120 coding region was sequenced in 8-10 clones for each sample.
Highlights
We report the results of a Phase II clinical trial of VRX496, an HIV-based vector encoding a 937-nt long antisense (AS) RNA targeting the gp[120] coding region of HIV-1 env gene [1-3]
Materials and methods Autologous CD4+ T lymphocytes from HIV-infected subjects were genetically modified ex vivo with the vector, expanded, and 10-80 billion vector-modified cells were reinfused into patients
Longitudinal effects of the therapy on HIV-1 env evolution were analyzed in 17 subjects sampled both pre-infusion and monthly postinfusion for 6 to 12 months
Summary
We report the results of a Phase II clinical trial of VRX496, an HIV-based vector encoding a 937-nt long antisense (AS) RNA targeting the gp[120] coding region of HIV-1 env gene [1-3]. Materials and methods Autologous CD4+ T lymphocytes from HIV-infected subjects were genetically modified ex vivo with the vector, expanded, and 10-80 billion vector-modified cells were reinfused into patients.
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call